Zhang LY, Yin YH, Wang XJ. Advances in the mechanism of action of metformin in pituitary tumors. World J Meta-Anal 2023; 11(5): 144-150 [DOI: 10.13105/wjma.v11.i5.144]
Corresponding Author of This Article
Xue-Jian Wang, MD, PhD, Professor, Surgeon, Department of Neurosurgery, The Affiliated Hospital 2 to Nantong University, No. 666 Victory Road, Chongchuan District, Nantong 226000 Jiangsu Province, China. 6841441@163.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Meta-Anal. Jun 18, 2023; 11(5): 144-150 Published online Jun 18, 2023. doi: 10.13105/wjma.v11.i5.144
Advances in the mechanism of action of metformin in pituitary tumors
Long-Yao Zhang, Yu-Hua Yin, Xue-Jian Wang
Long-Yao Zhang, Xue-Jian Wang, Department of Neurosurgery, The Affiliated Hospital 2 to Nantong University, Nantong 226000, Jiangsu Province, China
Yu-Hua Yin, Department of Neurosurgery, Renji Hospital, Shanghai Jiao Tong University, Shanghai 226000, China
Author contributions: Wang XJ and Zhang LY contributed to conceptualization; Zhang LY contributed to writing the original draft preparation; Yin YH contributed to review and editing of the manuscript; All authors have read and agreed to the final version of the manuscript.
Supported bythe Science and Technology Program of Nantong Health Committee, No. MA2019003, No. MA2021017, No. Key003; Science and Technology Program of Nantong City, NO. MS12015016, and No. JCZ2022040; and Kangda College of Nanjing Medical University, No. KD2021JYYJYB025, No. KD2022KYJJZD019, and No. KD2022KJJZZD022.
Conflict-of-interest statement: All the authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xue-Jian Wang, MD, PhD, Professor, Surgeon, Department of Neurosurgery, The Affiliated Hospital 2 to Nantong University, No. 666 Victory Road, Chongchuan District, Nantong 226000 Jiangsu Province, China. 6841441@163.com
Received: February 24, 2023 Peer-review started: February 24, 2023 First decision: March 9, 2023 Revised: March 20, 2023 Accepted: April 14, 2023 Article in press: April 14, 2023 Published online: June 18, 2023 Processing time: 111 Days and 22.5 Hours
Abstract
Pituitary tumors are common intracranial tumors, but when faced with drug-resistant or aggressive tumors, existing medical measures may not provide good control, leading to progression and deterioration. Metformin, a traditional hypoglycemic drug, has recently been discovered to have multiple functions including antitumor effects. There have been studies on the mechanism of metformin for the treatment of pituitary tumors, but it is uncertain whether it will provide new adjuvant or alternative therapies for the treatment of these tumors. We analyzed the potential mechanisms of action of metformin with respect to the inhibition of pituitary tumor growth and hormone secretion by reviewing the available literature.
Core Tip: Pituitary tumors are common intracranial tumors, but when faced with drug-resistant or aggressive tumors, existing medical measures may not provide good control, leading to progression and deterioration. Metformin, a traditional hypoglycemic drug, has recently been discovered to have multiple functions including antitumor effects. There have been studies on the mechanism of metformin for the treatment of pituitary tumors, but it is uncertain whether it will provide new adjuvant or alternative therapies for the treatment of these tumors. We analyzed the potential mechanisms of action of metformin on the inhibition of pituitary tumor growth and hormone secretion by reviewing the available literature.
